Cellzome was awarded a grant of up to Euro 3.85 million ($4.97 million) from the German government. The funds will be used to expand Cellzome’s technology platform into epigenetic target classes and subsequently its application to drug discovery projects in this area.
In addition, Cellzome will use the money to optimize its Kinobeads™ platform for diagnostic and translational medicine studies, which will allow the monitoring of target-drug interactions directly in patient material. This will improve the predictability of the safety and efficacy of new drug candidates in the clinic, the company reports. Overall, this grant enables Cellzome to extend its proteomics platform and to apply it even more broadly in drug discovery and development.
The grant, which will run for five years, is part of the HighTech initiative by the German Government .